Navigation Links
Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Date:8/19/2007

Interim Phase 1 Data Confirms Safety and Tolerability

PLYMOUTH MEETING, Pa., Aug. 8 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced interim data from the first Phase 1 clinical study of trodusquemine (MSI-1436) for the treatment of obesity. Anthony DelConte, M.D., Vice President, Clinical Research and Development, presented "Trodusquemine: A Novel Aminosterol for the Treatment of Obesity and Related Metabolic Disorders," during the IBC 12th Annual World Congress on Drug Discovery & Development of Innovative Therapeutics, August 6-8 in Boston.

The presentation summarized the clinical trial design of the single ascending dose Phase 1 study of MSI-1436 to evaluate safety and pharmacokinetics of the drug in healthy obese volunteers. Dr. DelConte provided interim data from the initial cohorts in the double-blind, randomized, placebo-controlled trial which included safety and pharmacokinetic (PK) data from 20 treated subjects and eight vehicle controls in four sequential dose groups. According to Dr. DelConte, PK profiles from the study thus far show a predictable pattern with minimal subject-to-subject variability and linearity across the range of doses studied. To date, no serious adverse events have been reported. It was emphasized that further study is needed to establish dose limiting toxicity and proof-of-concept in humans.

"These initial findings validate the preclinical safety and PK work done by Genaera scientists. We are encouraged by these findings and will continue to further characterize the safety profile and provide proof of concept for trodusquemine in obesity and type 2 diabetes management," commented Jack Armstrong, President and CEO. "We anticipate a
'/>"/>

SOURCE Genaera Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... QC , Nov. 28, 2014 /CNW Telbec/ - Ergoresearch ... and known under the « Équilibre, orthèses et ... Ended on September 30, 2014. All dollar amounts in the ... for the first quarter of fiscal year 2015 ended this ... by 2,1 % compared to revenues of $ 4 227 942 ...
(Date:11/28/2014)... LOS ANGELES , Nov. 28, 2014 According ... Americans over the course of their lifetime. For many, these ... chronic pain that is caused by a variety of factors. ... disc, surgery may be the best option. While there are ... Laser Discectomy performed by Seyed M. Rezaian , M.D., ...
(Date:11/28/2014)... Nov. 28, 2014  Valeant Pharmaceuticals International, Inc. ... announced that its wholly owned subsidiary, Valeant Pharmaceuticals ... of its outstanding 6.875% Senior Notes due 2018, ... on December 29, 2014 and has mailed an ... the redemption, approximately US$500 million aggregate principal amount ...
Breaking Medicine Technology:First Quarter Results fiscal year ended September 30, 2015 - Ergoresearch reports its results for the quarter ended September 30, 2014. 2First Quarter Results fiscal year ended September 30, 2015 - Ergoresearch reports its results for the quarter ended September 30, 2014. 3First Quarter Results fiscal year ended September 30, 2015 - Ergoresearch reports its results for the quarter ended September 30, 2014. 44 Advantages of Laser Back Surgery When Fixing a Herniated Disk 2Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 2
... fewer products in the pipeline and more at the ... commercial life of mature brands are critical to today,s ... as many as 10 years and billions of dollars ... To help biopharmaceutical companies more effectively ...
... Mass., Feb. 24, 2012  Haemonetics Corporation (NYSE: HAE ... Company effective March 5, 2012 as Vice President of ... ) Mr. Helsel, age 48, was with ... was Vice President of Operations for the Surgical Solutions ...
Cached Medicine Technology:Report Delivers ROI Analysis on Key Lifecycle Management Strategies Utilized by the Pharmaceutical Industry 2Dave Helsel Joins Haemonetics as Vice President of Global Manufacturing 2
(Date:11/28/2014)... York, NY (PRWEB) November 28, 2014 ... physical therapy techniques such as Dynamic Neuromuscular Stabilization, ... and gait/motion analysis. After moving to upgraded facilities ... and running clinic. Now, owner Dr. Lev Kalika ... performance and injury prevention lab in the country. ...
(Date:11/28/2014)... Agein.com, the Internet’s premier anti-aging web site focusing ... foremost experts in the industry, is releasing its top diet ... , “The official start of winter is still three weeks ... with an icy blast. After one of the worst winters ... usher in another brutal winter,” says Dr. Kevin J. McLaughlin, ...
(Date:11/28/2014)... Junk-A-Car ( http://www.junkacar.com ), one of the ... to help drivers, especially those in and around the ... areas deal with the especially harsh winter weather that ... the country. , With the high number of reported ... crashed and junk cars, Junk-A-Car is voluntarily ...
(Date:11/28/2014)... Mequon, Wisconsin (PRWEB) November 28, 2014 ... facial plastic surgeons , announced the expansion of Quintessa ... new center will be located at W307 N1497 Golf ... 2015. , According to Dr. Campbell, the new Delafield ... non-surgical procedures for patients, including: Botox, filler ...
(Date:11/28/2014)... 2014 Secura Consultants, based in ... marketing organizations in the country focused on delivering ... marketplace. Secura Consultants is proud to offer complimentary ... Group, a leading global financial company. , Many ... the ownership interest comes the need for business ...
Breaking Medicine News(10 mins):Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3Health News:Agein Corporation, a Leading Anti-Aging Company, Releases Top Diet and Personal Care Tips for Preventing Dry Skin this Season 2Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2
... -- Some women who inherit the BRCA1 or BRCA2 breast ... with breast cancer nearly a decade earlier than those who ... Researchers examined the family trees of 128 breast or ... determine the origins of the patients, cancer genes. "No ...
... around the world are reporting they are burned out and ... Pennsylvania School of Nursing,s Center for Health Outcomes and Policy ... Between 20 to 60 percent of nurses reported ... International Journal for Quality in Health Care , which ...
... of South American songbirds completed by the Department of ... Natural History, has discovered these birds differ dramatically in ... which indicates they are on the road to becoming ... show that species could change, that they were not ...
... Copenhagen have explored the active principles of a Danish mushroom ... particularly toxic towards cancer cells. The goal is to synthesise ... in future drug development. Asia has a long ... products. Many substances found in fungi are today registered as ...
... INDIANAPOLIS -- The health care system in the United States ... to the bedside, how to ensure more equitable use of ... how to pay for that care. The 10th ... of the journal Medical Care tackles key conceptual ...
... Over the past quarter century in Australia, cancer incidence rates ... are some of the findings of a recent study published ... Compared with any other disease group, cancer has ... two Australians developing cancer and one in five dying from ...
Cached Medicine News:Health News:Family Tree May Affect Diagnosis Age in Some Breast Cancers 2Health News:To keep nurses, improve their work environments 2Health News:Danish mushroom inspires cancer researchers 2Health News:Danish mushroom inspires cancer researchers 3Health News:Journal supplement presents strategies for introducing health care delivery innovation 2Health News:Study sheds light on cancer burden in Australia 2
... Aerosol Resistant Tips offer a safe alternative ... are designed for applications such as PCR(a), ... addition, ART Tips are excellent for tissue ... studies. ART Tips prevent aerosol contaminants and ...
... LBP Processor is a primary component of ... accessioning, processing, sampling, and slide preparation ... The MonoPrep LBP Processor produces high-quality sample ... broad range of cytology specimen types. It ...
... Like all Gilson disposable ... in a sterilized version. Each ... in medical device-quality plastic to ... Sterilization is guaranteed by the ...
200 L, Racked, Pre-sterilized, 96 tips/rack Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
Medicine Products: